Ipsen has patented engineered clostridial toxins with specific amino acid modifications that enhance their isoelectric points. These modifications, located outside the binding domain, apply to various botulinum neurotoxin serotypes and the tetanus neurotoxin, potentially expanding their medical applications. GlobalData’s report on Ipsen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Ipsen, Cancer treatment biomarkers was a key innovation area identified from patents. Ipsen's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered clostridial toxins with modified amino acids
The patent US12037369B2 describes an engineered clostridial toxin that features specific amino acid modifications in its translocation domain or light chain. The modifications include substitutions of acidic amino acids with basic or uncharged residues, as well as the insertion or deletion of certain amino acids. The engineered toxins include various serotypes of botulinum neurotoxin (BoNT/A, B, C, D, E, F, G) and tetanus neurotoxin (TeNT), each characterized by a defined isoelectric point (pI). Notably, the engineered light chain does not contain an E3 ligase recognition motif, ensuring that the modifications do not introduce such a motif.
The patent further details the extent of amino acid modifications, which can range from 1 to 90, with specific claims emphasizing at least three or between 4 and 40 modifications. The engineered toxins may also include substitutions with lysine or arginine residues at designated positions. Additionally, the patent outlines methods for producing these engineered toxins, including the expression of nucleic acids in host cells, and methods for activating the toxins through protease treatment. The engineered clostridial toxins are proposed for use in preventing or treating diseases and conditions, as well as for cosmetic applications, highlighting their potential therapeutic and aesthetic benefits.
To know more about GlobalData’s detailed insights on Ipsen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
